Authors
Latest:
Digital Transformation: What's the Cost of Doing Nothing?Right now, the smartest incumbents are channeling the forces of disruption to their own ends, leading digital transformation in order to avoid being left behind, writes Tony Owens.
Latest:
Atypical Visible Particles: Can Users and Makers Find Common Ground?In April 2012, industry experts discussed the issue of atypical visible particles in pharmaceutical raw materials, including excipients, at the joint International Pharmaceutical Excipient Council’s (IPEC) Regulatory Conference and ExcipientFest-Americas Conference in San Juan, Puerto Rico
Latest:
Pharma's Most Productive Innovators: The Top TenConsultancy firm IDEA Pharma has released what it calls a ‘Productive Innovation Index’, which ranks pharmaceutical companies based on their ability to successfully commercialize new innovations.
Latest:
Why "Episodes" Matter for DoctorsA customer "episode" is a key unit of management that can produce significant growth and cost savings, writes George Eliades.
Latest:
New Product Launch Playbook: Shaking up Status Quo in Pharma MarketingIn this demanding environment, yesterday’s product launch playbook can no longer be relied upon to yield the expected patient or business outcomes, writes Boris Bogdan.
Latest:
How to Select the Right Data Partner to Benefit Your BusinessLexisNexis Risk Solutions takes you inside the key considerations of making the all-important choice to partner with a data provider. Go beyond the well-polished sales pitches and understand the underlying implication of finding the right fit across 5 critical areas of business.
Latest:
It’s Time for a Chief Adherence OfficerOp-Ed: The best way to capitalize on the potential revenue influx from enterprise-level drug adherence programs is to create room at the executive table for a Chief Adherence Officer.
Latest:
Lessons on the Innovation JourneyRani Therapeutics CEO Mir Imran recounts the lessons he's learned in founding more than 20 life sciences companies and developing more than 400 patents.
Latest:
Building a Key Account Organization: 5 Power QuestionsIf companies are serious about building a sustainable organization for their employees and becoming a partner to key accounts, they need to be prepared to remodel their whole business around it, writes Miranda Wheatley Price.
Latest:
Leveraging Lab Data in Advent of Personalized MarketingLaboratory testing has become a critical access point for sales teams in the age of personalized medicine.
Latest:
Piecing Together the Pricing Puzzle: The Midterm ElectionsThere is no magic bullet that will dramatically impact drug pricing to everybody’s liking. But a stepwise approach involving a series of reforms, including taking advantage of the next midterm elections, could point the path toward a solution.
Latest:
What Can Pharmaceutical Companies do to Feel Better About Reputation?Reputation Institute study finds that the reputation of pharma companies is in decline and might get worse before it gets better.
Latest:
Nurse Educators: Bridging China's Patient Care GapChina's nurse educator program aims to improve quality of care and make life simpler for physicians handling high patient load. Sebastian Bather reports.
Latest:
Pragmatic AI in PharmaRon Wince explains how Pragmatic AI allows organizations to start with the basics, create immediate business value and ROI and then increase adoption as their comfort, capabilities and confidence increases.
Latest:
Connecting the 5 Spheres of People-Based MarketingFrom persistent identity to cloud marketing driven by AI, managing holistic experience is now the hallmark of brand leadership. Croom Lawrence and Kent Groves explains how people-based marketing plays a key role.
Latest:
Can Realistic Training Devices Help Make a Blockbuster?Realistic, multisensory training devices can contribute to a drug’s reception in the eyes of both patients and healthcare practitioners, writes Paul Sullivan.
Latest:
Beyond the Merits: Generic Company Defense StrategiesJosh Reisberg outlines the foundation of a broad, overall defense strategy for generic companies embroiled in Hatch-Waxman patent infringement litigations.
Latest:
Value-Based Purchasing for Prescription Drugs Takes a Leap Forward in State MedicaidThe U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) are commitment to support value-based purchasing (VBP) of prescription drugs in Medicaid, despite headlines of CMS’s rejection of a Massachusetts request to make changes in its Medicaid prescription drug benefit.
Latest:
Pathways to Potential in Europe's Pharmerging MarketsFilip Conic outlines the market-access approaches and commercial strategies to unlock the growth potential in the Southeastern and Eastern European region.
Latest:
Patient Communications: Why Pharma Leaders Should Think Like Social MarketersBy exploring how social marketers think, pharma can unlock tried-and-tested ways to bring measurable value to their patients, writes Patrick Ladbury and Oliver Childs.
Latest:
Early-Development Strategy for PTE in Biologics Given Unknowns in the LawThe importance of early development strategy and planning for biologic patent term extension.
Latest:
A Seat at the Strategy TableHow navigating compliance risks requires so much more than policies and procedures.
Latest:
Patient & Customer-Centric CommercializationOutlining a real-world example in which building and operationalizing a patient- and customer-centric commercialization strategy drove a successful launch from a “standing start.”
Latest:
Patient & Customer-Centric CommercializationOutlining a real-world example in which building and operationalizing a patient- and customer-centric commercialization strategy drove a successful launch from a “standing start.”
Latest:
Patient & Customer-Centric CommercializationOutlining a real-world example in which building and operationalizing a patient- and customer-centric commercialization strategy drove a successful launch from a “standing start.”
Latest:
Early-Development Strategy for PTE in Biologics Given Unknowns in the LawThe importance of early development strategy and planning for biologic patent term extension.
Latest:
EMA Relocation Countdown: Some Industry ViewpointsRaman Sehgal talks to three industry leaders for their insights on the challenges faced across the life science sector and how the EMA needs to respond.
